Freya Pharma Solutions develops Lybrido, a pharmaceutical treatment for women experiencing Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Interest/Arousal Disorder (FSIAD), which are characterized by reduced sexual desire and arousal. The company’s research-backed approach targets the neurobiological mechanisms of sexual excitation, providing clinically relevant improvements in women's sexual health and well-being.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many women experience Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Interest/Arousal Disorder (FSIAD), characterized by reduced sexual desire, arousal, and related distress. Current treatment options for these conditions are limited and may not adequately address the complex neurobiological factors involved. This can lead to decreased self-esteem, relationship difficulties, and a diminished overall quality of life for affected women.
Solution
Freya Pharma Solutions is developing Lybrido, a pharmaceutical treatment specifically designed to address HSDD and FSIAD in women. Lybrido targets the neurobiological mechanisms underlying sexual excitation and inhibition to improve sexual desire and arousal. Clinical studies have demonstrated statistically significant improvements in women's sexual experiences with Lybrido, offering a clinically relevant solution for women who are relatively insensitive to sexual cues and experience difficulties with arousal. The company's approach acknowledges the complexities of women's sexual health, moving beyond one-size-fits-all solutions.
Target Audience
The primary target audience includes women experiencing Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Interest/Arousal Disorder (FSIAD), as well as the healthcare providers who treat them.
Features
- Pharmaceutical formulation targeting neurobiological mechanisms of sexual excitation and inhibition.
- Designed for women with FSIAD (or HSDD) who are relatively insensitive to sexual cues.
- Developed from 15 years of research.
- Clinical studies have shown statistically and clinically relevant improvements in women’s sexual experiences.